Evidence map›Paper›PMID 28698271›Full record

ArticleJournal of the American Society of Nephrology : JASN2017

Mannose-Binding Lectin Levels Could Predict Prognosis in IgA Nephropathy.

Wei-Yi Guo, Li Zhu, Si-Jun Meng, Su-Fang Shi, Li-Jun Liu, Ji-Cheng Lv, Hong Zhang

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. A Rare Genetic Defect ofFrontiers in immunology · 2019
    Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Complement System Inhibitors in Nephrology: An Update-Narrative Review.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Targeting complement in IgA nephropathy.Clinical kidney journal · 2023
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wei-Yi GuoRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Li ZhuRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China; funnyzhuli@bjmu.edu.cn.
Si-Jun MengRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Su-Fang ShiRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Li-Jun LiuRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Ji-Cheng LvRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Hong ZhangRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Peking University · CNPeking University First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IgA nephropathy (IgAN) is characterized by infections followed by episodic gross hematuria. Deficiency of mannose-binding lectin (MBL) is associated with recurrent infection in many diseases, but controversy exists regarding the role of MBL in IgAN. Here, we measured

Indexed as

AdultFemaleGlomerulonephritis, IGAHumansMaleMannose-Binding LectinMetabolism, Inborn ErrorsPrognosisRetrospective StudiesMannose-Binding LectinIgA nephropathyMBLrenal outcome

Identifiers

PMID28698271
PMCPMC5661287
OpenAlexW2735326181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.